TRDA
$11.31-0.67 (-5.59%)
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's ...
Recent News
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +290.39% and +11.93%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +11.26% and +2.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline
Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.